DRUG INTERACTIONS AMONG PATIENTS WITH HYPERTENSION TAKING ANGIOTENSINCONVERTING ENZYME INHIBITORS IN AN INDONESIAN HOSPITAL by Sari, Santi Purna et al.
ISSN - 0975-7058 
Vol 10, Special Issue 1, 2018
DRUG INTERACTIONS AMONG PATIENTS WITH HYPERTENSION TAKING ANGIOTENSIN-
CONVERTING ENZYME INHIBITORS IN AN INDONESIAN HOSPITAL
SANTI PURNA SARI1*, AFI FAUZIYAH DARAJAT1, BINAR NURSANTI2
1Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, 16424, Indonesia. 2Division of Pharmacy, Karya Bhakti 
Pratiwi Hospital, Bogor, 16880, Indonesia. Email: santisari@farmasi.ui.ac.id
Received:  29 June 2018, Revised and Accepted: 26 September 2018 and 24 October 2018
ABSTRACT
Objective: This study aimed to analyze the drug interactions associated with angiotensin-converting enzyme (ACE) inhibitors for treating hypertension 
at Karya Bhakti Pratiwi Hospital between July and December 2016.
Methods: This was an analytical, descriptive, cross-sectional study based on the prescription and medical record data of hospitalized patients treated 
with an ACE inhibitor and one or more other drugs. Data were included by purposive sampling.
Results: The final analysis was conducted with 120 prescriptions from 71 patients. We found that ACE inhibitors were associated with 139 potential 
interactions with other drugs in 75 prescriptions (53.96%); of these, 52 were major interactions and 87 were moderate interactions. The Mann–
Whitney U-test confirmed that the potential drug interactions were significantly associated with polypharmacy (p<0.05), but the Chi-square test 
showed no association with either gender or pathophysiology (p>0.05). Finally, the Kruskal–Wallis test revealed no significant relationship between 
age and potential drug interactions (p>0.05).
Conclusion: The final analysis was conducted with 120 prescriptions from 71 patients. We found that ACE inhibitors were associated with 139 
potential interactions with other drugs in 75 prescriptions (53.96%); of these, 52 were major interactions and 87 were moderate interactions. The 
Mann–Whitney U-test confirmed that the potential drug interactions were significantly associated with polypharmacy (p<0.05), but the Chi-square 
test showed no association with either gender or pathophysiology (p>0.05). Finally, the Kruskal–Wallis test revealed no significant relationship 
between age and potential drug interactions (p>0.05).
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INTRODUCTION
Hypertension is a frequently occurring cardiovascular disease [1]. 
The American Heart Association estimates that it affects 80 million 
adults in the United States alone. In Indonesia, hypertension is also a 
prevalent non-communicable chronic disease, which affected 25.8% 
of the population in 2013 [2]. Angiotensin-converting enzyme (ACE) 
inhibitors are a key class of antihypertensive and are the first-line 
option in certain instances, such as in patients with diabetes or chronic 
renal failure. These drugs may be administered alone or with other 
hypertensives for improving efficacy, and they typically need to be taken 
for long periods [1,3]. Combined with the fact that patients treated 
with ACE inhibitors frequently have comorbidities that also require 
treatment, these factors increase the potential for drug interactions 
that can harm the patient.
According to the Micromedex® Interaction Checker, which can be used 
to check for potential drug interactions, ACE inhibitors have major 
interactions with 21 other drugs and moderate interactions with 16 
other drugs. In some instances of major interactions, medical treatment 
can be required if they are life-threatening or risk causing permanent 
damage. Similarly, moderate interactions may require additional 
therapy for preventing a patient’s clinical status from worsening. 
The following four major factors influence drug interactions: Age, 
polypharmacy, disease status, and genetics. Literature reviews are 
required for clarifying the frequency of possible interactions caused by 
the use of ACE inhibitors and other drugs in patients with hypertension 
because there is a lack of current data. At Bhakti Pratiwi Hospital, 
hypertension is among the top 10 most frequently treated diseases, 
resulting in antihypertensive being prescribed in large quantities.
In this research, we aimed to clarify the rates of major and moderate 
interactions between ACE inhibitors and other drugs.
METHODS
We conducted descriptive research using a retrospective cross-
sectional study design. All data were obtained from prescription 
and medical records for the period from July to December 2016. The 
study population comprised all inpatients of Bhakti Pratiwi Hospital 
who received ACE inhibitors. Data were included if patients were 
prescribed an ACE inhibitor with one or more other drugs (including 
other antihypertensive), were aged ≥18 years, and were diagnosed with 
hypertension. We excluded any data for prescriptions with unclear, 
incomplete, or untraceable medical records.
After the data were collected, researchers screened the ACE inhibitors 
against other drugs in the same prescription using the 2017 Micromedex 
Solution application from Truven Health Analytic, Stockley’s Drug 
Interaction 8th Edition textbook, Drug Interaction Textbook Facts, and 
related journals. Data were initially analyzed using univariate analysis of age, 
sex, polypharmacy, and potential interaction data. Subsequently, bivariate 
analysis was used for determining whether age, gender, polypharmacy, 
and pathophysiology affected the potential for drug interactions. These 
four factors were then hypothetically tested using IBM SPSS for Windows, 
Version 20 (IBM Corp., Armonk, NY, USA). A value of p<0.05 indicated that 
there was a significant difference between the two variables.
RESULTS AND DISCUSSION
A total of 155 prescriptions met our inclusion criteria, of which 35 
also met the exclusion criteria. Ultimately, 120 prescriptions from 
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71 patients were suitable for inclusion. ACE inhibitor was more 
frequently used in females (59.15%), patients aged ≥60 years (38.03%), 
and those with no impairments of liver or kidney function (36.62%). 
Polypharmacy was identified in 67 prescriptions, and most cases 
received 5–6 drugs (50.75%). The occurrence of interactions with ACE 
inhibitors is summarized in Table 1, with 75 of the 120 prescriptions 
(53.96%) having a combined total of 139 interactions (52 were major 
and 87 were moderate).
Major interactions
Captopril and allopurinol
We identified three cases of interaction between captopril and 
allopurinol (2.16%). Two patients did not experience hypersensitivity 
symptoms, but one suffered kidney failure. This result was not 
comparable to that in other studies, in which eight cases (35.25%) of 
such interaction was shown [4]. The mechanism of interaction between 
captopril and allopurinol is unknown, and it should be considered 
that allopurinol use alone can cause severe hypersensitivity reactions, 
especially if the patient has renal failure. Studies conducted by Halevy 
et al. showed that the using ACE inhibitors and allopurinol were not 
associated with an increased risk of Stevens–Johnson syndrome and 
toxic epidermal necrolysis [5].
Captopril and digoxin
In this study, we identified six cases (4.32%) of interaction between 
captopril and digoxin. The use of digoxin with other drugs requires 
special attention because digoxin has a narrow therapeutic window 
of approximately 0.5–2.0 ng/mL; however, this figure is not absolute 
and varies with individual differences [6]. The interaction of these 
drugs typically increases plasma digoxin levels because captopril can 
lead decreases in the glomerular filtration rate and reduced tubular 
secretion [7]. However, research by Iraz et al. failed to show that a 
combination of these drugs can increase plasma digoxin levels [6].
Captopril and angiotensin receptor blockers (ARB)
Two cases were prescribed an ARB and an ACE inhibitor, with one case 
each (0.72%) of interactions for captopril-candesartan and captopril-
valsartan. This may happen probably because doctors and pharmacists 
already knew that a combination of these two drugs can harm patients. 
Hyperkalemia can occur when ACE inhibitors are combined with 
ARBs. The effect is presumed to occur through each binding to adrenal 
receptors, interfering with the effects of angiotensin II on aldosterone 
secretion, and thereby decreasing potassium excretion by the kidney. 
In a meta-analysis of 33 randomized trials comparing the safety of 
ACE inhibitors and ARBs alone or in combination, it was reported that 
concurrent use increased the incidence of hyperkalemia, hypotension 
events, renal failure, and drug withdrawal by 55%, 66%, 41%, and 27%, 
respectively [8]. Interaction between ACE inhibitors and ARBs is rarely 
identified in studies of drug interactions, making it difficult to find 
previous research data for comparison with our own.
ACE inhibitors and potassium chloride
There were 14 cases (10.07%) of interaction between captopril and 
potassium chloride (KCl) and five cases (3.59%) of interaction between 
ramipril and KCl. This differed slightly from two previous studies 
showing that ACE inhibitor interactions with KCl resulted in 22 cases 
(35.85%) [9] and five cases (27.78%) [10,11]. ACE inhibitors have a 
potent retention effect due to decreased aldosterone levels, and this 
is exacerbated by the addition of supplemental potassium. In practice, 
increased potassium levels occur clinically only if other factors are 
present. Retrospective studies of hyperkalemia among inpatients 
found that the main risk factors were potassium supplementation, 
severe renal dysfunction, ACE inhibitor/antagonist angiotensin II, use 
of potassium-sparing diuretics, and diabetes mellitus. Moreover, the 
presence of two or more of these risk factors was associated with the 
rapid development of hyperkalemia [12].
Captopril and cotrimoxazole
Based on this research, there were four cases (2.88%) of interaction 
between captopril and cotrimoxazole. Previous studies have shown that 
more than half of all patients taking ACE inhibitors were hospitalized for 
hyperkalemia after taking cotrimoxazole for urinary tract infection [13]. 
Trimethoprim, a component of cotrimoxazole, has a comparable structure 
and pharmacology to the potassium-sparing diuretic amiloride. This 
antibiotic competitively inhibits the potassium channel in the epithelium 
of the distal nephron, thus interfering with potassium excretion in 
the kidneys and can lead to hyperkalemia when given in isolation. 
The combination of cotrimoxazole with an ACE inhibitor significantly 
increases the risk of hospitalization due to hyperkalemia [14]. Studies 
have shown that more than half of all patients taking ACE inhibitors were 
hospitalized for hyperkalemia after taking antibiotics (i.e., cotrimoxazole) 
to treat a urinary tract infection [13].
ACE inhibitors and spironolactone
In this study, interactions were observed between captopril and 
spironolactone in 16 cases (11.51%) and between ramipril and 
spironolactone in two cases (1.44%). The simultaneous use of these 
ACE inhibitors with spironolactone can cause hyperkalemia: The ACE 
inhibitors decrease the amount of aldosterone and cause potassium 
retention, while spironolactone works additively as an aldosterone 
antagonist to lower aldosterone levels further [12]. Given that 
aldosterone is a major hormonal stimulus for potassium excretion 
in the urine [15], hyperkalemia can occur when its levels decrease. 
In 2015, another study reported that 1062 patients were treated for 
hyperkalemia due to combination therapy with an ACE inhibitor and 
spironolactone [16].
Moderate interactions
Captopril and nonsteroid anti-inflammatory drugs (NSAIDs)
The total number of cases of ACE inhibitor interactions with NSAIDs was 
20 (13%) in this study, which was greater than that reported previously 
(n=35; 4.2%) [17]. Captopril interacts with virtually all NSAIDs, which can 
cause the effectiveness of captopril decrease. Alone, NSAIDs can increase 
blood pressure in elderly patients, purportedly through the following 
mechanisms: (1) Inhibiting enzymes that produce prostaglandins, 




Captopril and allopurinol 3 (2.16)
Captopril and digoxin 6 (4.32)
Captopril and candesartan 1 (0.72)
Captopril and potassium chloride 14 (10.07)
Ramipril and potassium chloride 5 (3.59)
Captopril and cotrimoxazole 4 (2.88)
Captopril and spironolactone 16 (11.51)
Ramipril and spironolactone 2 (1.44)
Captopril and valsartan 1 (0.72)
Moderate interactions
Captopril and acarbose 1 (0.72)
Captopril and aspirin 24 (17.26)
Captopril and mefenamic acid 1 (0.72)
Captopril and antacid 2 (1.44)
Captopril and celecoxib 1 (0.72)
Captopril and dexketoprofen 1 (0.72)
Captopril and furosemide 17 (12.23)
Ramipril and furosemide 4 (2.88)
Captopril and glimepiride 5 (3.59)
Captopril and gliquidone 2 (1.44)
Captopril and insulin 2 (1.44)
Captopril and ketorolac 11 (7.91)
Ramipril and ketorolac 1 (0.72)
Captopril and meloxicam 4 (2.88)
Captopril and metformin 11 (7.91)
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resulting in decreased renal perfusion, (2) increasing sodium and water 
resistance, and (3) decreasing prostacyclin production.
Captopril and aspirin
We identified 24 cases (17.26%) of interaction between captopril and 
aspirin, comparable to research on drug interactions that identified 
33 cases of such interaction [18]. Aspirin may inhibit the effects of ACE 
inhibitors by inhibiting cyclooxygenase enzymes so that prostaglandins 
do not form, causing vasoconstriction, decreased cardiac output, and 
worsening heart failure (Baxter, 2010). The interaction between 
aspirin and ACE inhibitors has only been reported for high-dose aspirin 
(2.4 g/day), not low-dose aspirin, and to date.
Captopril and antacid
There were three cases (2.16%) of interaction between captopril and 
antacids in the present research. In previous research among 10 healthy 
subjects, antacids were shown to be capable of reducing the area under 
the curve of single-dose captopril (50 mg) by 40%, albeit without 
altering the rate of blood pressure decrease. Overall, interaction-
related evidence between ACE inhibitors is limited, and the mechanism 
by which antacids decrease captopril absorption is unclear and needs 
further investigation [12].
ACE inhibitors and furosemide
Based on this research, there were 17 cases (12.23%) of captopril 
and furosemide interactions and four cases (2.88%) of ramipril and 
furosemide interactions. This was slightly different from data obtained in 
Iran, where interactions were only reported between ACE inhibitors and 
furosemide in two patients (0.98%) [19]. The coadministration of ACE 
inhibitors with strong diuretics or thiazide diuretics is normally safe and 
effective, but some patients develop a first-dose hypotensive syndrome 
(i.e., dizziness, head lightness, and fainting), which occurs when some 
patients treated for chronic renal failure and taking a high dose of a strong 
diuretic use an ACE inhibitor for the first time [20]. This hypotension can 
be aggravated by several conditions, such as heart failure, renovascular 
hypertension, hemodialysis, high levels of renin and angiotensin, sodium 
intake, dehydration, diarrhea, vomiting, and hypovolemia, and/or 
sodium deficiency due to high-dose diuretic use. The risk of hypotension 
was reported to be greater at furosemide doses ≥80 mg daily, so it is 
recommended that ACE inhibitors should be started in these patients 
under strict supervision. Clinicians should consider stopping or lowering 
the doses of diuretics for at least 24 h before administration. If this is not 
possible, the response to initial ACE inhibitor administration needs to be 
monitored for 2 h, or until the blood pressure is stable.
Captopril and antidiabetic medications
Interactions were observed between captopril and metformin (11 cases; 
7.91%), captopril and glimepiride (3 cases; 2.16%), captopril and acarbose 
(1 case; 0.72%), captopril and gliquidone (2 cases; 1.44%), and captopril 
and insulin (2 cases; 1.44%). Research, in 2015, showed less significant 
results with up to seven cases of interaction between captopril and insulin 
and four cases of interaction between captopril and metformin [21]. The 
mechanism by which ACE inhibitors increase insulin sensitivity remains 
unclear and is clinically questionable [22]. However, two mechanisms 
have been proposed. First, captopril may provide a vasodilatory effect 
which then increases the access of insulin and glucose to skeletal muscle 
tissue, a key site of insulin-mediated glucose uptake [23]. Second, the 
increased bradykinin levels associated with ACE inhibitor use may 
increase vascular permeability and increase the delivery of glucose and 
insulin to tissues. Although they provided potential mechanisms as to 
how captopril may improve insulin sensitivity, the researchers failed to 
show any significant differences between controls and dogs administered 
captopril and antidiabetic medications simultaneously.
Bivariate analysis
There was no relationship between sex and potential drug interactions 
(p=0.722, Chi-square test), consistent with research in Saudi Arabia, 
which also showed no association (p=0.361) [22]. However, there was 
a significant relationship between polypharmacy and drug interactions 
(p<0.05; Mann–Whitney U-test), again consistent with the research 
from Saudi Arabia (p<0.001) [24]. Increasing the number of drugs 
administered to a patient increases the potential for drug interactions. 
This is more common in elderly patients who usually suffer more than 
one disease, requiring the provision of multiple drugs and increasing 
the risk of polypharmacy [25].
The Chi-square test results comparing pathophysiology with potential 
drug interactions also showed that there was no relationship between 
the two factors (p>0.05). Theoretically, changes in liver and kidney 
function associated with age produce objective changes in drug 
clearance and metabolism. For example, as the body ages, blood flow 
through the liver decreases and the clearance of some drugs can be 
inhibited by as much as 30–40% [25]. Some interaction effects will also 
develop more rapidly if the patient has comorbid renal failure, such as 
when the patient develops interactions due to captopril-allopurinol, 
captopril-digoxin, captopril-spironolactone, and captopril-furosemide 
combinations.
Finally, we use the Kruskal–Wallis tests for assessing the relationship 
between age and potential drug interaction, which revealed that 
there was no relationship (p=0.071). Comparable results were shown 
in a study of 227 patients (p=0.99) [26]. However, the fact that our 
results approached significance (p<0.05), may have been because our 
age variation was not evenly distributed (e.g., one patient was aged 
24 years) and because the cohort was too small to show a relationship 
(71 patients).
CONCLUSION
In our hospital from July to December 2016, patients treated with ACE 
inhibitors for hypertension tended to be female, be aged ≥60 years, 
have polypharmacy (5–6 drugs), and have no liver or kidney disease. 
ACE inhibitors were associated with potential interactions with other 
drugs on 75 prescriptions (53.96%), with 52 major interactions and 
87 moderate interactions identified. The most common interaction 
was between captopril and aspirin (24 cases, 17.26%). The bivariate 
analyses indicated that there was a relationship between potential 
drug interactions and polypharmacy (p<0.05), but that there was no 
relationship between potential drug interactions and either sex, age, or 
pathophysiology (p>0.05).
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